Autoinjector vs. syringe: which delivers sonelokimab better?
NCT ID NCT06994936
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study in 120 healthy adults compared two methods of giving a single dose of sonelokimab: a prefilled syringe and an autoinjector. The goal was to see if both methods deliver the same amount of drug into the body. Researchers measured drug levels in the blood and checked for side effects. The results will help decide if the autoinjector can be used in future studies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- sonelokimab
- What this could lead to
- If the autoinjector works as well as the syringe, patients may have a more convenient way to receive this medication.
- What could go wrong
- This is an early-phase study in healthy volunteers, not patients. It only checks drug levels, not whether the drug treats any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
120 people
The number who actually took part.
- Started
-
Jun 2025
- Finished
-
Nov 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants must be between 18 and 55 years of age with suitable veins for cannulation or repeated venipuncture . * Participants must have a body weight greater than 40 kg and body mass index (BMI) between 21 and 30 kg/m2, inclusive. * Participants who are overtly healthy as determined by medical evaluation including medical history, physician examination, laboratory tests, and cardiac monitoring. * Female participants are eligible to participate if they are not pregnant or breastfeeding * Male participants must be willing to use a condom when sexually active with a partner of childbearing potential during the study, unless surgically sterile. Exclusion Criteria: * History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study. * History of clinically significant infections. * Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric. * History of hypersensitivity, intolerance, or severe adverse reaction to any drug compound, any history of anaphylaxis or angioedema, or any history of severe food allergy/intolerance requiring systemic treatment. * Participants with transaminase and liver function test results outside of the normal reference range, following a confirmatory test, if appropriate * Participants with other clinically significant laboratory test results that are likely to introduce additional risk factors or interfere with the study procedures or interpretation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Relative bioequivalence are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Site
London, United Kingdom